All Oncology News

The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.

ctDNA-Guided Adjuvant Atezolizumab Boosts DFS, OS in Muscle-Invasive Bladder Cancer

October 20th 2025

Adjuvant atezolizumab improved DFS and OS in patients with muscle-invasive bladder cancer who tested positive for ctDNA after radical cystectomy.

CheckMate 8HW Data Further Support Nivolumab/Ipilimumab as a SOC Option in First-line MSI-H/dMMR mCRC

October 20th 2025

Nivolumab plus ipilimumab improved PFS and response rates vs nivolumab alone in MSI-H/dMMR mCRC, with no new safety concerns.

Camrelizumab Plus Famitinib Extends PFS vs Chemotherapy in First-Line Metastatic Cervical Cancer

October 20th 2025

Camrelizumab plus famitinib led to superior PFS and OS outcomes vs chemotherapy in frontline recurrent/metastatic cervical cancer.

Bemarituzumab/Chemo Combo Translates to OS Advantage in FGFR2b+ Gastric/GEJ Cancer

October 20th 2025

Bemarituzumab/mFOLFOX6 produced an OS advantage over placebo/mFOLFOX6 in FGFR2b-overexpressing gastric/GEJ cancer; this was attenuated at longer follow-up.

Adjuvant Alectinib Impresses in Updated ALINA Results for ALK+ NSCLC

October 20th 2025

Long-term data from the ALINA trail continued to support the use of adjuvant alectinib in resected, ALK-positive, early stage non–small cell lung cancer.

IO102-IO103 Plus Pembrolizumab Improves PFS in Treatment-Naive Advanced Melanoma

October 20th 2025

IO102-IO103 plus pembrolizumab was associated with a clinically relevant improvement in median progression-free survival.

New Toolset by Yale Researchers Boosts Efficacy of CAR-T Cells Targeting Blood and Solid Cancers

October 20th 2025

Telisotuzumab Adizutecan Demonstrates Activity, Tolerability in Locally Advanced/Metastatic PDAC

October 20th 2025

Telisotuzumab adizutecan displayed early activity in locally advanced/metastatic PDAC.

Perioperative Pembrolizumab Benefits Persist at 5-Year NSCLC Update

October 20th 2025

Pembrolizumab before and after surgery reduced the risk of death compared with placebo for patients with early-stage non–small cell lung cancer.

FDA Awards Breakthrough Therapy Designation to Bezuclastinib for Non-Advanced Systemic Mastocytosis

October 20th 2025

Bezuclastinib received breakthrough therapy designation for pretreated non-advanced systemic mastocytosis, as well as for smoldering systemic mastocytosis.

Sacituzumab Govitecan Plus Pembrolizumab Upholds QOL, Delays Physical Decline in mTNBC

October 20th 2025

Sacituzumab govitecan plus pembrolizumab may maintain quality of life in patients with previously untreated, PD-L1–positive metastatic TNBC.

FDA Accepts BLA Resubmission for RP1 Plus Nivolumab in Advanced Melanoma

October 20th 2025

Will the FDA approve a resubmitted biologics license application for RP1 plus nivolumab in advanced melanoma after progression on anti–PD-1 therapy?

Raludotatug Deruxtecan Demonstrates Promising Efficacy, Safety in Platinum-Resistant Ovarian Cancer

October 20th 2025

Raludotatug deruxtecan demonstrates antitumor activity and manageable safety in platinum-resistant ovarian cancer.

DESTINY-Breast09 Subgroup Data Show Clinically Meaningful PFS Benefit T-DXd/Pertuzumab in HER2+ Breast Cancer

October 20th 2025

T-DXd plus pertuzumab generated consistent PFS benefits among HER2+ breast cancer subgroups.

TROPION-Breast02 Data Support Dato-DXd as New First-Line SOC in Triple-Negative Breast Cancer

October 20th 2025

Dato-DXd improved PFS, OS, and response rates compared with chemotherapy in first-line TNBC, with manageable safety, per phase 3 TROPION-Breast02 data.

ADC Iza-Bren Generates Responses and Improves PFS vs Chemo in Metastatic NPC

October 19th 2025

The bispecific ADC iza-bren improved ORR and led to more durable responses vs chemotherapy in heavily pretreated recurrent or metastatic NPC.

Ivonescimab Plus Chemo Might Be a New SOC in Advanced Squamous NSCLC

October 19th 2025

Ivonescimab plus chemotherapy improved PFS and response rates vs tislelizumab in advanced squamous NSCLC, with a manageable safety profile.

Tiragolumab/Atezolizumab/Bevacizumab Fails to Significantly Improve PFS in Advanced/Metastatic HCC

October 19th 2025

The SKYSCRAPER-14 trial did not show a PFS benefit with tiragolumab plus atezolizumab and bevacizumab in untreated HCC, missing its coprimary end point.

212Pb-DOTAMTATE Yields Responses and Shows Disease Control in Pretreated Advanced GEP-NETS

October 19th 2025

212Pb-DOTAMTATE produced responses with a manageable safety profile in patients with SSTR-positive, PRRT-exposed, unresectable or metastatic GEP-NETs.

Lutetium Lu 177 Vipivotide Tetraxetan Plus ARPI/ADT Yields Superior PFS in PSMA+ mHSPC

October 19th 2025

Lutetium Lu 177 vipivotide tetraxetan plus an ARPI and ADT improved rPFS in metastatic hormone-sensitive prostate cancer.